Company Overview
Snapshot
Founded in March 2017 by Edu Strul and Yehushua Gur, EyeJets operates with 1–10 employees. The company has secured funding across two rounds, with its most recent funding event occurring in February 2023.
Business overview
EyeJets is developing innovative smart glasses technology that projects digital information, including images, video, and augmented and virtual reality content, directly into the retina using a laser-scanning system. This technology can be integrated into any pair of glasses and features eye-tracking capabilities. EyeJets targets both personal use and the healthcare sector, where its system can assist in the early diagnosis of conditions such as diabetes, hypertension, and glaucoma. The company operates within the Media & Entertainment Technologies sector, with applications in Digital Healthcare and Digital Medical Diagnostics.
Strategic signal
In September 2022, EyeJets garnered media attention for its retinal display technology, with articles highlighting its potential to usher in a 'screenless future' and redefine the smartphone experience. This signals strong market interest in the company's innovative approach to wearable technology and its potential to disrupt traditional digital display interfaces, positioning EyeJets as a key player in the evolving AR/VR and smart glasses landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is EyeJets' core technology?
- EyeJets is developing a system that projects digital information, including images, video, and augmented and virtual reality, directly into the retina using a special laser-scanning system in the center of the eye's vision area. This technology can be attached to any pair of glasses.
- When was EyeJets founded and by whom?
- EyeJets was founded in March 2017 by co-founders Edu Strul and Yehushua Gur.
- What are the potential applications of EyeJets' technology?
- EyeJets' technology can be used for personal needs, such as viewing digital content, and in the healthcare field for early diagnosis of various diseases like diabetes, hypertension, and glaucoma, leveraging its eye-tracking capabilities.